Optimization of Ridge Parameters in Multivariate Generalized Ridge Regression by Plug-in Methods

Abstract Generalized ridge (GR) regression for a univariate linear model was proposed simultaneously with ridge regression b

Preparation of UO_2 Fine Particle by Hydrolysis of Uranium(IV) Alkoxide

Fine particles of uranium(IV) dioxides were obtained by hydrolysis of uranium(IV) ethoxide which was synthesized by reacting uranium tetrachloride with sodium ethoxide. The monodispersed submicrometer particles were confirmed by SEM observation

AC magnetic susceptibility studies of single crystalline CeNiGe2 under high pressure

金沢大学大学院自然科学研究科環境計画The magnetic susceptibility of CeNiGe2 single crystal has been measured under high pressure up to 2.0 GPa. Although two anomalies are observed at TN1=4.0 K and at TN2=3.0 K at ambient pressure, TN2 disappears above 0.13 GPa, while TN1 still remains near 2.0 K up to 2.0 GPa. On the other hand, the peak height of the susceptibility curve decreases with increasing pressure, which may suggest that the correlation between conduction and f-electrons is strengthened by pressure. The Kondo temperature TK is estimated from the maximum of χc–T curve. TK is remarkably enhanced by applying pressure

Nucleotide sequence of the genes, encoding the pentaheme cytochrome (dmsC) and the transmembrane protein (dmsB) involved in dimethyl sulfoxide respiration from Rhodobacter sphaeroides f. sp. denitrificans

AbstractThe nucleotide sequence of the genes encoding a pentaheme cytochrome (dmsC) and a transmembrane protein (dmsB) were determined upstream of the dmsA gene encoding dimethyl sulfoxide reductase from Rhodobacter sphaeroides f. sp. denitrificans. dmsC and dmsB encode proteins of 404 and 226 amino acid residues, which show 40% and 26% identity to the pentaheme cytochrome TorC and the transmembrane protein TorD, respectively, of the trimethylamine N-oxide reduction system in Escherichia coli

Magnetic Phase Diagram of Ce1-xErxAl2 intermetallic compounds

The magnetic and thermal properties of Ce1−xErxAl2 compounds have been studied using electrical resistivity and magnetic susceptibility measurements. The magnetic ordering temperature continuously changes with a change from antiferro-magnetism (CeAl2) to ferro-magnetism (ErAl2) appears. The magnetic ordering temperature is continuously changed as a function of Er concentration x. A spin glass behavior was found between x = 0.08 and 0.4. The magnetic phase diagram was compiled as a function of x.Embargo Period 12 month

Thermal and magnetic properties in Ce1-xErxAl2 intermetallic compounds

The magnetic and thermal properties of Ce1−xErxAl2 compounds have been studied using specific heat, dc magnetization, and ac susceptibility measurements. All these compounds are isomorphic with the MgCu2 Laves phase, and the lattice parameter decreases almost linearly with the increasing Er concentration x. The dc magnetic susceptibility follows the Curie–Weiss law, and the Weiss temperature continuously changes from Θ = −24 K for x = 0 to Θ = 15 K for x = 1, indicating a change from antiferro-magnetism to ferromagnetism. Θ changes from negative to positive at around x = 0.2 where where a field-induced metamagnetic transition disappears. The magnetic ordering state continuously changes with the change in x from antiferromagnetic to ferromagnetic through a spin-glass-like behavior.Embargo Period 12 month

Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer?

BackgroundIt is controversial whether achieving stable disease leads to a survival benefit and whether the importance of achieving stable disease differs between cytotoxic agents and molecular targeted agents. To examine these questions, the authors retrospectively reviewed phase II and III studies in the second-line setting for advanced non-small cell lung cancer using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and cytotoxic agents separately.MethodsThe authors chose 45 trials for the chemotherapy group and nine for the EGFR TKI group by searching the PubMed database. All nine trials in the EGFR TKI group concern gefitinib and erlotinib.ResultsThe median survival time increased 0.0375 month with each 1% increase in stable disease rate (p = 0.039), and each 1% increase in response rate resulted in 0.0744 (p < 0.001) month of median survival time in the analysis combined with both cytotoxic agents and EGFR TKIs. Main and interaction terms for EGFR TKI treatment were not statistically significant. With respect to time to progression, only response rate showed a statistically significant relationship with survival.ConclusionsTo obtain response seems to be more important than to achieve stable disease for both cytotoxic agents and EGFR TKIs, although achieving stable disease is still valuable. The relationship between survival and response or stable disease appears similar for cytotoxic agents and EGFR TKIs

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer

Objectives Unsatisfactory efficacy of current treatments for advanced lung cancer has prompted the search for new therapies, with sorafenib, a multikinase inhibitor, being one candidate drug. This phase I trial was conducted to evaluate drug safety and pharmacokinetics as well as tumor response of sorafenib in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Methods Eligible patients received paclitaxel (200 mg/m2) and carboplatin (area under the curve [AUC]of 6 mg min mL−1) on day 1 and sorafenib (400 mg, twice daily) on days 2 through 19 of a 21-day cycle. Results Four of the initial six patients (cohort 1) experienced dose-limiting toxicities (DLTs), resulting in amendment of the treatment protocol. An additional seven patients (cohort 2) were enrolled, two of whom developed DLTs. DLTs included erythema multiforme, hand-foot skin reaction, and elevated plasma alanine aminotransferase in cohort 1 as well as gastrointestinal perforation at a site of metastasis and pneumonia in cohort 2. Most adverse events were manageable. One complete and six partial responses were observed among the 12 evaluable patients. Coadministration of the three drugs had no impact on their respective pharmacokinetics. Conclusion The present study confirmed that sorafenib at 400 mg once daily in combination with carboplatin AUC 5 mg min mL−1 and paclitaxel 200 mg/m2 is feasible in Japanese patients with advanced NSCLC. The results of this study also showed that this combination therapy had encouraging antitumor activity and was not associated with relevant pharmacokinetic interaction in Japanese NSCLC patients